FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3141754952> ?p ?o ?g. }

• W3141754952 endingPage "100177" @default.
• W3141754952 startingPage "100177" @default.
• W3141754952 abstract "We assessed national- and state-level geographic variations among patients with a history of ≥1 major atherosclerotic cardiovascular disease (ASCVD) event in: (1) the proportion of patients with retrospectively identified 2018 American College of Cardiology/American Heart Association guideline very high-risk (VHR) ASCVD criteria; (2) utilization of guideline-directed lipid-lowering therapy (LLT); and (3) the proportion of patients with persistent low-density lipoprotein cholesterol (LDL-C) elevations despite statin and/or ezetimibe use.A retrospective cohort study using the Prognos LDL-C database linked to IQVIA longitudinal medical and prescription claims databases. The study period was from January 01, 2011, to November 30, 2019 and the index period was from January 01, 2016, to November 30, 2019; the index date was defined as the most recent LDL-C test during the index period. The study included patients aged ≥18 years at index who had a measured LDL-C level during the index period and had ≥1 inpatient/outpatient claim for ASCVD during the 5-year pre-index period.Of patients with any ASCVD (N=4652,468), 1537,514 (33.1%) patients had ≥1 major ASCVD event. Among patients with ≥1 major ASCVD event, the VHR ASCVD criteria were retrospectively identified in 1139,018 (74.1%) patients; Hawaii had the highest (81.7%) and Colorado the lowest (65.0%) proportion of these patients. Nationally, 48.8% and 50.2% of patients with ≥1 major ASCVD event and retrospectively identified VHR ASCVD criteria, respectively, had current LLT use; Massachusetts and Colorado had the highest and lowest proportions, respectively. After standardizing for age and sex, 57.3% and 58.8% of patients with ≥1 major ASCVD event and retrospectively identified VHR ASCVD criteria, respectively, had LDL-C ≥70 mg/dL (≥1.8 mmol/L) despite statin and/or ezetimibe use, with substantial state-level variations observed.The study highlights high rates of elevated LDL-C and pervasive underuse of LLT in health-insured patients with a history of major ASCVD events treated in the United States, with state-level geographic variations observed." @default.
• W3141754952 created "2021-04-13" @default.
• W3141754952 creator A5004865159 @default.
• W3141754952 creator A5006822602 @default.
• W3141754952 creator A5012376116 @default.
• W3141754952 creator A5037872394 @default.
• W3141754952 creator A5042508373 @default.
• W3141754952 creator A5048919979 @default.
• W3141754952 creator A5054726198 @default.
• W3141754952 creator A5057887317 @default.
• W3141754952 date "2021-06-01" @default.
• W3141754952 modified "2023-09-27" @default.
• W3141754952 title "Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States" @default.
• W3141754952 cites W1974005985 @default.
• W3141754952 cites W2019071303 @default.
• W3141754952 cites W2022109882 @default.
• W3141754952 cites W2029199268 @default.
• W3141754952 cites W2046039931 @default.
• W3141754952 cites W2121470298 @default.
• W3141754952 cites W2150048145 @default.
• W3141754952 cites W2158753098 @default.
• W3141754952 cites W2164089346 @default.
• W3141754952 cites W2181130900 @default.
• W3141754952 cites W2319635690 @default.
• W3141754952 cites W2335730369 @default.
• W3141754952 cites W2580792129 @default.
• W3141754952 cites W2592054892 @default.
• W3141754952 cites W2595226750 @default.
• W3141754952 cites W2605944906 @default.
• W3141754952 cites W2753797556 @default.
• W3141754952 cites W2889582862 @default.
• W3141754952 cites W2900034165 @default.
• W3141754952 cites W2901527506 @default.
• W3141754952 cites W2907385487 @default.
• W3141754952 cites W2941765605 @default.
• W3141754952 cites W2946341517 @default.
• W3141754952 cites W2971575888 @default.
• W3141754952 cites W3006057482 @default.
• W3141754952 cites W4254714439 @default.
• W3141754952 cites W4294383028 @default.
• W3141754952 doi "https://doi.org/10.1016/j.ajpc.2021.100177" @default.
• W3141754952 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8315617" @default.
• W3141754952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34327500" @default.
• W3141754952 hasPublicationYear "2021" @default.
• W3141754952 type Work @default.
• W3141754952 sameAs 3141754952 @default.
• W3141754952 citedByCount "11" @default.
• W3141754952 countsByYear W31417549522021 @default.
• W3141754952 countsByYear W31417549522022 @default.
• W3141754952 countsByYear W31417549522023 @default.
• W3141754952 crossrefType "journal-article" @default.
• W3141754952 hasAuthorship W3141754952A5004865159 @default.
• W3141754952 hasAuthorship W3141754952A5006822602 @default.
• W3141754952 hasAuthorship W3141754952A5012376116 @default.
• W3141754952 hasAuthorship W3141754952A5037872394 @default.
• W3141754952 hasAuthorship W3141754952A5042508373 @default.
• W3141754952 hasAuthorship W3141754952A5048919979 @default.
• W3141754952 hasAuthorship W3141754952A5054726198 @default.
• W3141754952 hasAuthorship W3141754952A5057887317 @default.
• W3141754952 hasBestOaLocation W31417549521 @default.
• W3141754952 hasConcept C126322002 @default.
• W3141754952 hasConcept C142724271 @default.
• W3141754952 hasConcept C167135981 @default.
• W3141754952 hasConcept C2426938 @default.
• W3141754952 hasConcept C2776839432 @default.
• W3141754952 hasConcept C2778657065 @default.
• W3141754952 hasConcept C2779134260 @default.
• W3141754952 hasConcept C2780182762 @default.
• W3141754952 hasConcept C2908647359 @default.
• W3141754952 hasConcept C2909478654 @default.
• W3141754952 hasConcept C71924100 @default.
• W3141754952 hasConcept C98274493 @default.
• W3141754952 hasConcept C99454951 @default.
• W3141754952 hasConceptScore W3141754952C126322002 @default.
• W3141754952 hasConceptScore W3141754952C142724271 @default.
• W3141754952 hasConceptScore W3141754952C167135981 @default.
• W3141754952 hasConceptScore W3141754952C2426938 @default.
• W3141754952 hasConceptScore W3141754952C2776839432 @default.
• W3141754952 hasConceptScore W3141754952C2778657065 @default.
• W3141754952 hasConceptScore W3141754952C2779134260 @default.
• W3141754952 hasConceptScore W3141754952C2780182762 @default.
• W3141754952 hasConceptScore W3141754952C2908647359 @default.
• W3141754952 hasConceptScore W3141754952C2909478654 @default.
• W3141754952 hasConceptScore W3141754952C71924100 @default.
• W3141754952 hasConceptScore W3141754952C98274493 @default.
• W3141754952 hasConceptScore W3141754952C99454951 @default.
• W3141754952 hasFunder F4320307105 @default.
• W3141754952 hasLocation W31417549521 @default.
• W3141754952 hasLocation W31417549522 @default.
• W3141754952 hasLocation W31417549523 @default.
• W3141754952 hasLocation W31417549524 @default.
• W3141754952 hasOpenAccess W3141754952 @default.
• W3141754952 hasPrimaryLocation W31417549521 @default.
• W3141754952 hasRelatedWork W2118584914 @default.
• W3141754952 hasRelatedWork W2172629117 @default.
• W3141754952 hasRelatedWork W2511594969 @default.
• W3141754952 hasRelatedWork W2613263923 @default.
• W3141754952 hasRelatedWork W2757805866 @default.

• next